Quarterly ResultMay 5, 2026, 07:08 AM
Pfizer Q1 Revenue +5.4% to $14.45B; EPS $0.47, down 9.6%
AI Summary
Pfizer Inc. reported its first-quarter 2026 financial results, with total revenues increasing by 5.4% to $14.45 billion. However, net income attributable to common shareholders decreased by 9.4% to $2.69 billion, resulting in diluted earnings per share of $0.47, down 9.6% year-over-year. The company also announced an in-licensing arrangement with Sciwind Biosciences for commercialization rights in Mainland China and completed the exit of its investment in ViiV, generating $1.875 billion in cash proceeds.
Key Highlights
- Total revenues increased 5.4% to $14.45 billion for Q1 2026.
- Net income attributable to Pfizer Inc. common shareholders decreased 9.4% to $2.69 billion.
- Diluted EPS was $0.47, down 9.6% from $0.52 in Q1 2025.
- Pfizer obtained exclusive commercialization rights for ecnoglutide in Mainland China from Sciwind Biosciences.
- Completed exit of 11.7% investment in ViiV, receiving $1.875 billion in cash proceeds.
- Net cash provided by operating activities rose to $2.62 billion from $2.34 billion.
- Restructuring charges and acquisition-related costs decreased to $100 million from $678 million.
- Acquired in-process R&D expenses increased to $137 million from $9 million.
Price Impact
More from PFE